ArticleCancer cell international2025
KAT6A acetyltransferase accelerates colorectal cancer progression through upregulating BRD1 protein expression via acetylation modification.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches.Acta crystallographica. Section D, Structural biology · 2026Article
- Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies worldwide. KAT6A, which functions as an acetyltransferase, has been identified as an oncogenic factor in numerous cancers; however, its role in CRC has not been fully elucidated. This study evaluated the malignant behavior of CRC cells using colony formation assay, EdU incorporation assay, and Transwell assay. Quantitative real-time PCR, immunoblotting, immunoprecipitation (IP), co-immunoprecipitation (Co-IP), and mouse xenograft models were employed to explore the underlying mechanisms. Our findings revealed that KAT6A was overexpressed in CRC and associated with poor patient outcomes. Genetic or pharmacological inhibition of KAT6A significantly inhibited cell viability, proliferation, migration, and invasion. Mechanistically, KAT6A promoted BRD1 acetylation, which enhanced the stability of BRD1 protein. Collectively, our research demonstrated that KAT6A upregulates BRD1 protein expression through acetylation, thereby promoting CRC progression. These results suggest KAT6A-mediated BRD1 acetylation as a novel and promising therapeutic target for CRC, contributing valuable insights into the molecular mechanisms underlying CRC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.